Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Maxim Group Downgrades Comcast Corp (CMCSA) to Hold
-
Maxim Group Starts NetApp (NTAP) at Buy
-
Maxim Remains Bearish on Sell-Rated JCPenney (JCP) into Q3 Results
-
Macy's (M) Comps and EPS Estimates Cut Ahead of Q3 Print - Maxim Group
-
Æterna Zentaris (AEZS) PT Slashed at Maxim Group, But 'Don't Sell Now'
-
Teva Pharma (TEVA) PT Raised to $70 at Maxim Group
-
Sucampo Pharmaceutical (SCMP) PT Lifted to $14 at Maxim Group on Robust Amitza Growth
-
AEterna Zentaris (AEZS) PT Lifted to $6 at Maxim Group
-
Maxim Group Downgrades NIC Inc. (EGOV) to Sell
-
Gladstone Land Announces Exercise of Over-Allotment Option
-
Axion Power (AXPW) Closes 1.88M Common, Warrants Offering
-
Maxim Group Upgrades Madison Square Garden (MSG) to Buy
-
Maxim Group Starts Sophiris Bio (SPHS) at Buy
-
UPDATE: Cytori Therapeutics (CYTX) FDA News Positive, Maxim Group Says; Sees New Strategy Emerging
-
Maxim Group Upgrades Southwestern Energy (SWN) to Buy
-
Maxim Group Starts MAXIMUS, Inc. (MMS) at Buy
-
Maxim Group Starts CACI International (CACI) at Hold
-
Maxim Group LLC Expands Equity Research Platform With the Appointment of a Senior Enterprise & Consumer Technology Analyst
-
Maxim Group Starts Syntel, Inc. (SYNT) at Buy
-
Maxim Group Starts NIC Inc. (EGOV) at Hold
-
Cytori Therapeutics (CYTX) Closes on $13.5M in Financing
-
Notable Analyst Rating Changes 10/10: (IPXL) (EA) (AON) Upgraded; (JCP) (GRPN) (BDSI) Downgraded
-
Pre-Open Stock Movers 10/10: (EXAS) (APT) (LAKE) Higher; (GTAT) (PKT) (MTW) (MCHP) (TSLA) Lower (more...)
-
UPDATE: Maxim Group Downgrades J. C. Penney (JCP) to Sell; Analyst Says Its 3-Year Outlook is Optimistic
-
UPDATE: Maxim Group Upgrades Sucampo Pharmaceuticals (SCMP) to Buy
-
PlacementTracker Publishes Third Quarter 2014 PIPE Market League Tables
-
Cytori Therapeutics (CYTX) Announces $13.5M Registered Direct Placement
-
Maxim Group Assumes Star Bulk Carriers (SBLK) at Buy
-
Maxim Group Assumes Paragon Shipping Inc. (PRGN) at Buy
-
Maxim Group Starts Euroseas Ltd. (ESEA) at Buy
-
Maxim Group Assumes Baltic Trading Limited (BALT) at Buy
-
Maxim Group Comments on Omeros (OMER) Following New Omidria Supply Agreement
-
Tekmira Pharma (TKMR) Target Price Lifted to $31 at Maxim Group on Accelerated Ebola Assumptions
-
Lpath (LPTN) Closes 3.6M Registered Direct Offering
-
Quest Resource (QRHC) Closes $18M Offering of Stock and Warrants
-
Gladstone Land (LAND) Prices 1.15M Offering at $12.28/Share
-
Gladstone Land Corporation Announces Pricing of Common Stock Offering
-
Pre-Open Stock Movers 9/24: (LPCN) (MACK) (ACOR) Higher; (ECTE) (ATOS) (GTI) Lower (more...)
-
After-Hours Stock Movers 9/23: (LPCN) (BBBY) (ZSPH) Higher; (ATOS) (GTI) (AIR) Lower (more...)
-
Gladstone Land (LAND) Announces 1.15M Common Stock Offering
-
Gladstone Land Corporation Announces Common Stock Offering
-
Maxim Group Reiterats Bullish Stance on Galmed (GLMD) Following FDA Fast-Track Status; Funded Through Proof-of-Concept Studies in NASH
-
Maxim Group Calls Tekmira Pharma (TKMR) News 'Ground Breaking'
-
Pre-Open Stock Movers 9/19: (CNQR) (DRC) (JBLU) Higher; (ESI) (CRR) (TIBX) Lower (more...)
-
Quest Resource Holding (QRHC) Prices 9M Common Offering at $1.99/Share
-
Lpath (LPTN) Announces 3.6M Registered Direct Offering
-
After-Hours Stock Movers 9/18 (CNQR) (MCP) (JBLU) Higher; (TIBX) (RHT) (ORCL) Lower (more...)
-
Quest Resource Holding (QRHC) Reports Common Stock Offering
-
Foamix Pharmaceuticals (FOMX) IPO Opens Sharply Higher; Pauses on Volatility
-
Foamix Pharmaceuticals (FOMX) Prices 6.7M IPO at $6/Share

